Mimix Biotherapeutics’ innovative skin graft a step closer to the market

Headquartered at the Switzerland Innovation Park in Biel / Bienne, mimiX has developed a next-generation 3D bioprinting platform using Sound Induced Morphogenesis (SIM). SIM was developed as a result of 10+ years of research and development efforts incubated at the AO Foundation. It uses sound in conjunction with cells, stem cells, spheroids, organoids & bioactives to create tissue relevant architectures (patterns).

Mimix’ lead product is FastSkin, a skin graft for acute and chronic wound treatment. The proof of principle of FastSkin was supported by Eurostars EUREKA program. In Q2 2022 the company closed a seed round which was joined by AO Foundation, the German technology group Heraeus and private investors.

Recently a pre-clinical demonstration showed the usability, safety and clinical efficacy of the technology of the mimiX device. The company is launching a funding round in January 2023 to accelerate U.S. market clearance and market launch.

SIM has several relevant advantages compared to other 3D biofabrication solutions: It requires significantly fewer cells (thousands vs. millions), has shorter processing times (seconds vs. weeks) and is closer to nature’s design and safer. mimiX has embedded its base SIM technology into cymatiX, a discovery platform for a large range of applications, from life sciences to drug development, cellular agriculture and performance materials.

FastSkin creates new opportunities in the treatment of complex wounds, a major social burden and clinical unmet need in oncology and chronic wounds. FastSkin is a dermal substitute produced during wound-dressing session at point-of-care. It harnesses the power of micrografts, (micro-scale biological tissue entities obtained from a biopsy of healthy skin), which are during the bio-production process with mimiX’ medical device evenly distributed in a blood clot. This dermal substitute is applied to the wound bed by surgeons or specialized wound-care nurses. Thanks to the new technology it should take only 5-10 minutes from the moment of micrografting to obtain a ready-to-implant skin graft at point of care.

(Press release / SK)